Clinical trials · California
Prostate Cancer Recurrent clinical trials in California
We’re tracking 41 recruiting prostate cancer recurrent studies with a site in California — including Phase 1, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in California
- NCT06173349RecruitingPhase 1
New bladder therapy for BCG-resistant bladder cancer
This trial tests a new treatment for bladder cancer that does not respond to standard BCG therapy. The treatment uses tiny particles (micelles) that deliver a chemotherapy drug directly into the bladder, aiming to destroy cancer cells without needing surgery.
Sacramento, CaliforniaAges 18 years+ - NCT05176483RecruitingPhase 1
New drug combinations for advanced solid tumors
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
Palo Alto, CaliforniaAges 18 years+ - NCT07711002RecruitingPhase 3
Saruparib with standard therapy for metastatic hormone-sensitive prostate cancer
This trial tests a new drug called saruparib, which may help keep prostate cancer from growing. It is for men whose cancer has spread and who have already received certain treatments. The study combines saruparib with a standard hormone therapy to see if it works better than the hormone therapy alone.
Beverly Hills, CaliforniaAges 18 years+ - NCT06780670RecruitingPhase 2/Phase 3
Comparing a new treatment to standard care for advanced prostate cancer
This study tests a new drug (AAA817) against the usual treatments for men with advanced prostate cancer that has stopped responding to a type of targeted radiation therapy (Lu-PSMA). The goal is to see if the new drug can slow the cancer's growth better than standard options.
Los Angeles, CaliforniaAges 18–100 - NCT06084338RecruitingPhase 2
Focused Radiation Therapy Without Hormone Therapy for Advanced Prostate Cancer
This trial tests whether giving focused radiation to many cancer spots (SBRT) can work without using testosterone-blocking hormone therapy. It is for men whose prostate cancer has spread and is no longer responding to low testosterone, and who have already tried one of the newer hormone drugs.
West Los Angeles, CaliforniaAges 18 years+ - NCT05939414RecruitingPhase 3
Study of radioactive drug for prostate cancer that has spread a little
This study tests a radioactive drug (177Lu-PSMA-617) compared to no immediate treatment in men with prostate cancer that has returned and spread to a few spots (oligometastatic). It aims to see if this treatment delays the spread of cancer and improves outcomes.
Los Angeles, CaliforniaAges 18–100 - NCT06447103RecruitingPhase 2
New scan to find kidney cancer after surgery
This trial tests a special PET scan to see if it can better find leftover kidney cancer after surgery compared to a standard CT scan. You may qualify if you had kidney cancer surgery within the last 4-16 weeks and are at high risk of the cancer coming back.
Los Angeles, CaliforniaAges 18 years+ - NCT07725796RecruitingPhase 1
Study of UGN-501 for recurrent bladder cancer
This study tests an experimental medicine called UGN-501 given directly into the bladder. It is for people whose bladder cancer has come back despite previous treatments, such as BCG therapy. The goal is to find the best dose and see how safe and effective it is.
Bakersfield, CaliforniaAges 18 years+ - NCT03418961RecruitingPhase 3
Study of heart-risk management for metastatic HER2 breast cancer
This trial follows people with metastatic HER2-positive breast cancer who are at higher risk for heart damage while on HER2-targeted therapy. Some participants are randomly assigned to different monitoring/heart-protection approaches to see what best helps keep the heart safe.
Mission Hills, CaliforniaAges 18 years+ - NCT07114601RecruitingPhase 1
Study of LY4257496 for people with GRPR-positive solid tumors
This trial tests a new drug, LY4257496, in people with certain types of cancer that have a protein called GRPR on their cells. The study aims to see if the drug can help shrink tumors or slow the cancer's growth.
Duarte, CaliforniaAges 18 years+ - NCT07000084RecruitingPhase 3
Testing gemcitabine with BCG for returning bladder cancer
This trial tests whether adding a chemotherapy drug called gemcitabine to the usual BCG therapy can help prevent bladder cancer from coming back again. If you have had BCG before and your cancer returned, this study might offer a more effective treatment option.
Irvine, CaliforniaAges 18 years+ - NCT06682728RecruitingPhase 2
Treating high-risk bladder cancer after surgery
This trial tests a combination of two drugs (sacituzumab govitecan and nivolumab) given after surgery to prevent the return of muscle-invasive bladder cancer. It is for patients whose cancer has a high chance of coming back despite surgery.
Orange, CaliforniaAges 18 years+ - NCT05521698RecruitingPhase 1
Bicalutamide for early-stage bladder cancer
This trial tests whether the drug bicalutamide can help men with early-stage (non-invasive) bladder cancer, which has not grown into the bladder muscle. It is given before surgery to see if it can reduce the chance of the cancer coming back. Participants will be randomly assigned to receive bicalutamide or a placebo before their scheduled surgery.
Los Angeles, CaliforniaAges 18 years+ - NCT06770582RecruitingPhase 2
Adding immunotherapy to radiation for bladder cancer
This trial tests whether adding the immunotherapy drug pembrolizumab to radiation therapy works as well as or better than the usual chemotherapy given with radiation for a type of bladder cancer that has not invaded the muscle. It is for people whose cancer came back or has high-risk features and who would otherwise need to have their bladder removed.
Bakersfield, CaliforniaAges 18 years+ - NCT07003295RecruitingPhase 2
Glofitamab for mantle cell lymphoma that returned after CAR-T
This trial tests a new drug, glofitamab, for mantle cell lymphoma that came back or didn’t respond after CAR-T cell therapy. It aims to see if glofitamab can shrink or control the lymphoma.
Duarte, CaliforniaAges 18 years+ - NCT05058651RecruitingPhase 2/Phase 3
Atezolizumab plus chemo for advanced neuroendocrine cancer outside the lung
This trial tests whether adding an immunotherapy drug called atezolizumab to standard chemotherapy helps people with advanced neuroendocrine carcinoma (a rare and aggressive cancer) that started outside the lung. The goal is to see if the combination works better than chemo alone.
Anaheim, CaliforniaAges 18 years+ - NCT07089641RecruitingPhase 1
Study of ERAS-801 for recurrent or newly diagnosed glioblastoma with EGFR changes
This trial tests an experimental drug called ERAS-801 for people with a type of brain cancer called glioblastoma or gliosarcoma that has a specific genetic change (EGFR amplification or mutation). The study has two groups: one for people whose tumor has come back after treatment, and another for older adults (70+) who are newly diagnosed. The drug targets the EGFR pathway, which may help slow tumor growth.
Los Angeles, CaliforniaAges 18 years+
Where these studies are running in California
Institutions with a site for the recruiting prostate cancer recurrent studies listed above.
- City of Hope · 3 studies
- UC Irvine Health/Chao Family Comprehensive Cancer Center · 2 studies
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care · 2 studies
- UCLA Jonsson Comprehensive Cancer Center · 2 studies
- University of California, Davis · 2 studies
- USC Norris Comprehensive Cancer Center · 2 studies
- VA Greater LA Healthcare System · 2 studies
- VA Palo Alto Health Care System · 2 studies
What taking part in a prostate cancer recurrent study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Prostate Cancer Recurrent trials in other states
Common questions
- Are there prostate cancer recurrent clinical trials in California?
- Yes. We're currently tracking 41 recruiting prostate cancer recurrent studies with a site in California, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a prostate cancer recurrent study in California?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in California to take part?
- Not necessarily. These studies have a site in California, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a prostate cancer recurrent trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New prostate cancer recurrent studies open in California regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.